NTLA-2001
Intellia Therapeutics
['crispr']
crispr-based in vivo genome editing in humans well tolerated, shows consistent and durable ttr reductions over 4-6 mo #aha2022 
Non-Profit Founder/Leader | ?? Doc | Artist | Scientist | Educator | News Anchor https://t.co/usmuA3tKft | RT ? endorse | Disclaimer: https://t.co/bwmE2O3U5W